We are live on ! Find out more
COCP icon

Cocrystal Pharma
COCP

16 hedge funds and large institutions have $1.01M invested in Cocrystal Pharma in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0.21% less ownership

Funds ownership: 7.3% → 7.1% (-0.21%)

6% less funds holding

Funds holding: 17 → 16 (-1)

21% less capital invested

Capital invested by funds: $1.28M → $1.01M (-$262K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
7
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$31.3K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$27.4K
3
TRCT
Tower Research Capital (TRC)
New York
+$2.51K
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.4K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$65

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$92.4K
2
JP Morgan Chase
JP Morgan Chase
New York
-$2.58K
3
BlackRock
BlackRock
New York
-$494
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$7
5
Bank of America
Bank of America
North Carolina
-$6
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$386K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$176K +$1.4K +900 +0.7%
BlackRock
3
BlackRock
New York
$103K -$494 -317 -0.4%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$86.4K – – –
Morgan Stanley
5
Morgan Stanley
New York
$83K -$92.4K -59,283 -50%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$74.5K +$27.4K +17,586 +51%
State Street
7
State Street
Massachusetts
$35K – – –
UBS Group
8
UBS Group
Switzerland
$28.4K +$31.3K +20,091 +12,031%
Northern Trust
9
Northern Trust
Illinois
$17.1K – – –
Bank of America
10
Bank of America
North Carolina
$12.6K -$6 -4 -0%
TRCT
11
Tower Research Capital (TRC)
New York
$10.4K +$2.51K +1,612 +28%
JP Morgan Chase
12
JP Morgan Chase
New York
$776 -$2.58K -1,653 -75%
VL
13
Vima LLC
Michigan
$461 +$9 +6 +3%
Wells Fargo
14
Wells Fargo
California
$130 +$2 +1 +1%
NL
15
NVWM LLC
Pennsylvania
$118 – – –
Fidelity Investments
16
Fidelity Investments
Massachusetts
– -$7 -4 Closed
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
– +$65 +42 +467%

COCP Hedge Fund Activity: Q1 2024 in Review

16 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q1 2024, worth a combined $1.01M — down 21% from $1.28M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of COCP and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.

The largest buyer was UBS Group, adding an estimated $31.3K. The largest seller was Morgan Stanley, cutting an estimated $92.4K.

  • 16 institutional investors held Cocrystal Pharma (COCP) as of Q1 2024, down from 17 in Q4 2023.
  • Funds reported $1.01M of Cocrystal Pharma stock for Q1 2024, down 21% quarter-over-quarter.
  • 0 funds opened new Cocrystal Pharma positions in Q1 2024 and 1 closed out, a net change of -1 holder.
  • The largest Cocrystal Pharma buyer in Q1 2024 was UBS Group, an estimated $31.3K added.
  • The largest Cocrystal Pharma seller in Q1 2024 was Morgan Stanley, an estimated $92.4K sold.

Based on aggregated 13F filings for Q1 2024.